Drugs / NILK-2301
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06663839 | Apr 2024 → Oct 2025 overdue | colorectal cancer | Light Chain Bioscience - Novimmune SA | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NILK-2301 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06663839 ↗ |
| Target | CEACAM5 | “a Bispecific CEACAM5 X CD3 Engaging Antibody” NCT06663839 ↗ |